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SuMMArY Autoimmune bullous diseases are systemic disorders with auto-
antibodies that result in blisters. Aim of this study was to indicate the spectrum 
and treatment modalities of five types of bullous disorders most prevalent in 
the south of Iran: pemphigus vulgaris (PV), pemphigus foliaceus (PF), epider-
molysis bullousa aquisita (EBA), bullous pemphigoid (BP), and pemphigoid 
gestationis (PG). Patients with PV, PF, BP, EBA, and PG were included in this 
study. The data regarding the age, sex, and the treatment used for PV, PF, and 
BP were recorded and analyzed in our center, a tertiary referral center. T-test 
and Mann-Whitney test for independent samples were used for the analysis 
of parametric and nonparametric variables, respectively. Chi-square test was 
used for frequencies. Of the 441 patients included in this study, 82.9% had 
PV, 4.7% PF, 8.5% BP, 1.5% EBA, and 1.3% PG. 93.5% of patients with PV, 95.3% 
with PF, and 100% with patients with BP were treated and responded to first 
line therapies with one or two medications.
The most frequent autoimmune bullous disease was PV, followed by PF. For PV 
and PF, combination of prednisolone and azathioprine was the most frequent 
first line medication. In the patients with BP, prednisolone monotherapy was 
the most frequent one. Only a minority of patients with PV and PF needed the 
third or fourth medications.
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InTroDuCTIon
Autoimmune bullous disorders (ABD) are a group 
of systemic disorders with autoantibodies that result 
in intraepidermal and subepidermal blisters (1). They 
need serious medical care, otherwise they have rela-
tively high mortality (2,3).
Limited research has been done worldwide on the 
epidemiology and treatment of ABD. In particular, 
only a small number of epidemiological studies are 
available about epidemic spectrum and treatment of 
various types of ABD in Iran. 
The aim of this study was to indicate the spectrum 
of five types of most prevalent bullous disorders in 
the south of Iran. We also determined the frequency 
of different types of ABD treatment.
PATIEnTS AnD METhoDS
During a 10 year period, the records of all the new 
patients admitted with bullous disease at Shiraz Uni-
versity of Medical Sciences (SUMS) dermatology cen-
ter were evaluated. This is the major tertiary referral 
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center for dermatologic diseases in the south of Iran. 
Private dermatologists also refer new bullous disorder 
patients to our tertiary center for better management 
and follow up. The diagnosis was made based on the 
clinical presentation, histopathology, and direct im-
munofluorescence. 
Five diseases were included in our study: pemphi-
gus vulgaris (PV), pemphigus foliaceus (PF), epider-
molysis bullousa aquisita (EBA), bullous pemphigoid 
(BP), and pemphigoid gestationis (PG). The data re-
garding the age, sex, and the treatment used for PV, 
PF, and BP were recorded and analyzed.
The SPSS statistical package was used for analysis. 
T-test and Mann-Whitney test for independent sam-
ples were used for all parametric and nonparametric 
variables analysis, respectively. Chi-square test was 
used for qualitative variables. In all statistical tests, 
P<0.05 was considered significant.
rESulTS
About 6400 patients with various dermatologic 
diseases were admitted during the 10 year period of 
the study. A total number of 441 patients with auto-
immune bullous disorders were included. 369 cases 
were diagnosed as PV (82.9% of the total cases). Table 
1 shows characteristics of different bullous diseases 
including the number, frequency, mean age, median 
age, age range, and sex ratio.
We studied different medical treatments used in 
our center for treating PV, PF, and BP. Out of the 369 
cases of PV, there were only 311 patients with avail-
able treatment data. The frequency of the 1st, 2nd and 
3rd line therapies for the cases are shown in Table 2 
and 3.
93.5% of patients with PV, 95.3% with PF, and 
100% of patients with BP responded to the 1st line 
therapies of one or two medications. 6.5% of patients 
with PV and 4.7% with PF needed the 2nd and 3rd line 
therapies in order to control the disease.
DISCuSSIon
ABDs are rare blistering diseases affecting the 
skin and mucosa. Their clinical and epidemiologic 
features vary according to geographic location and 
ethnic background. Few surveys have been done 
to describe the spectrum of ABD in our region. The 
SUMS dermatology center is the referral center for 
dermatology diseases for southern Iran, with about 
6.5 million inhabitants in this area. 
Epidemiology
441 ABD cases were included in the study. PV ac-
counted for the majority of cases (83.67%), followed 
by BP, PF, EBA, and PG. PV outnumbered other ABD 
cases; this finding is similar to studies conducted in 
most of the world, except Latin American counties, 
Mali, Tunisia and Finland: in these regions, other bul-
lous diseases such as fogo selvagem, PF, and pemphi-
gus erythematosus predominate (3-8).
Patients with PV and PF were predominantly men. 
This is in contrast to what has been noted in Germany, 
Kuwait, Switzerland, and the UK (9-12); studies from 
India, Saudi Arabia, Bangladesh, and China found the 
same predominance (13-16). Patients with BP were 
predominantly women, in line with previous studies 
(2,10,11). However, studies from China and Germany 
found that patients with BP were predominantly men 
(15,16). On the other hand, patients with EBA were 
also predominantly women in our study, as in Kuwait 
(11), but a study of north of Iran reports a male pre-
dominance (3).
The mean ages were 45.8 years for PV, 40.4 years 
for EBA, and 50.7 years for PF. The mean ages for PV 
and EBA are similar to what was found in the stud-
ies in the north of Iran, Saudi Arabia, and Singapore 
(3,13,17). PF mean age is relatively close to Korea and 
Japan, where the disease presented in the sixth and 
seventh decades (18,19). The mean age of patients 
with PG was 27.3 years, which is younger than that of 
the study from Sao Paulo (30.3 years) (20).




Mean ± SD of 
age at onset 
(years) 
% of patients No. of 
patients 
Autoimmune bullous 
disease   
1.1 : 1 21-89 44 45.8 ± 16.2 83.67 369 Pemphigus vulgaris 
1.1 : 1 22-75 51 50.7 ± 17.35 4.76 21 Pemphigus foliaceus 
1 : 1.23 21-90 65 64.1 ± 17.70 8.61 38  Bullous pemphigoid 




19-35 27 27.3 ± 5.32 1.36 6 Pemphigoid 
gestationis 
Table 1. The frequency and epidemiology of autoimmune bullous disease during a 10 year period
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Table 3. The frequency of 2nd and 3rd line therapies for autoimmune disease in resistant cases
BP was the second most common ABD in this study, 
PV being the most common. The ratio of PV to BP was 
9.7:1, which is close to the results from studies in the 
north of Iran, Kuwait, and China (11,15). The median 
age for BP was 65 years, which is similar to the results 
of the study of the north of Iran (59.4 years) (3). 
EBA was observed in 1.5% of patients, and PG ac-
counted for 1.3% of patients. Both estimates are high-
er than what was reported in the north of Iran (0.5% 
and 0.7%, respectively) (3). 
Treatments
Prednisolone with the dosage of 0.5 to 1.5 mg/kg 
is the first line medication that is used for ABD, and 
steroid sparing agents are added in an attempt to 
taper corticosteroids. For PV and PF, the combina-
tion of prednisolone and azathioprine was the most 
frequent first line medication with 68% and 47.6%, 
respectively. It was followed by monotherapy with 
prednisolone accounting for 18.6% and 38% in PV 
and PF, respectively.
In the BP group, prednisolone monotherapy (50%) 
was the most frequent medication, followed by pred-
nisolone in combination with azathioprine (26.3%). 
Dapsone was used more frequently (23.6%) in BP pa-
tients compared to PV and PF (1.2% and 9.5%, respec-
tively). Prednisolone in combination with mycophe-
nolate mofetil (1.2%) or cyclosporine (0.9%) was used 
as the first line therapy in a minority of PV cases.
The patients who did not respond to the first line 
medications were treated with the 2nd and 3rd line 
therapies. None of BP cases required the third line 
medication. Only a minority of PF patients (4.7%) 
needed the addition of the third medication, in which 
only the combination of prednisolone, azathioprine, 
and mycophenolate mofetil was used. 
In the PV group, the most commonly used third 
line medications were dapsone (2.9%), mycopheno-
late mofetil (1.6%), or cyclosporine (0.9%). The combi-
nation of prednisolone with mycophenolate mofetil 
and tacrolimus was used in 0.3% of patients, which 
was similar to the frequency of using the combina-
tion of prednisolone with cyclophosphamide and 
dapson (0.3%).
Only 0.3% of PV cases received the four drug com-
bination of prednisolone, azathioprine, mycopheno-
late mofetil, and dapson.
The more frequent use of the third and fourth 
medications in PV may imply the more severe nature 
of PV. In the study performed in Germany, more than 
50% of patients with PV received prednisolone as the 
first medication and azathioprine was added in 81% 
of cases, which is close to our results. In that study, 
azathioprine was added in 69% of patients with BP, 
which is higher than the findings of our study (26.3%). 
Immunosuppressive agents that were used as alter-
native were similar to those used in our center (21).
ConCluSIon
The present study was carried out in a tertiary re-
ferral center. Although most of ABD cases are referred 
to tertiary centers, the milder cases might be man-
aged in an outpatient setting and would not have 
been included in this study. Due to the retrospective 
nature of this study, we could not determine the ex-











PV (291) 18.6% (58) – 0.9% (3) 68% (212) 4.5% (14) 1.2% (4)
PF (20) 38% (8) – – 47.6% (10) – 9.5% (2)
BP (38) 50% (19) 5.2% (2) – 26.3% (10) – 18.4% (7)
DX: disease; PV: pemphigus vulgaris; PF: pemphigus foliaceus; BP: bullous pemphigoid; MM: mycophenolate mofetil




















PV (20) 2.9% (9) 1.6% (5) 0.9% (3) 0.3% (1) 0.3% (1) 0.3% (1)
PF (1) – 4.7% (1) – – – –
DX: disease; PV: pemphigus vulgaris; PF: pemphigus foliaceus; MM: mycophenolate mofetil
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